This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|December 3, 2020
Raw Material Delays Cut Pfizer Vaccine Production
Author(s)BioPharm International Editors
A longer-than-expected scale up of raw materials forces Pfizer to cut 2020 vaccine production in half.
Advertisement
Delays in the scale up of the raw material supply chain has caused Pfizer to cut its original projection of 100 million doses of its COVID-19 vaccines in 2020 to 50 million doses, according to a Reuters report.
A Pfizer spokesperson also cited later-than-expected clinical trial results as another reason for fewer doses being produced by the end of the year. The spokesperson noted, however, that changes to the production lines are complete and finished doses are being produced at a rapid pace, the Reuters report said.
When releasing early clinical trial data, Pfizer and BioNTech had anticipated a total of 100 million vaccine doses to be manufactured by the end of 2020, a projection that was maintained until mid-November 2020. However, in a recent question and answer thread, presented on Pfizer’s Twitter feed on Nov. 25, 2020, Angela Hwang, group president, Biopharmaceuticals, Pfizer, revealed that the anticipated number of doses to be manufactured before the end of the year was reduced by half.
The companies still anticipate a total of 1.3 billion doses of the vaccine to be manufactured in 2021. “We have ramped up manufacturing capabilities across the globe to meet the high demand due to the COVID-19 pandemic,” Hwang said in the Pfizer Twitter thread. “If the vaccine is authorized or approved, we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.”
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5